研究单位：[1]CSPC ZhongQi Pharmaceutical Technology Co.,Ltd.[2]The second people's hospital of neijiang Neijiang,Sichuan,China,641100[3]Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology Wuhan,Hubei,China,430022[4]Sichuan Cancer Hospital & Institute Chengdu,Sichuan,China,610041[5]Hubei Cancer Hospital Wuhan,Hubei,China,430079[6]Changsha Kexin Cancer Hospital Changsha,Hunan,China,413002[7]Yiyang Central Hospital Yiyang,Hunan,China,413002[8]The third Hospital of Nanchang Nanchang,Jiangxi,China,330000[9]The second hospital of Jinlin University Changchun,Jinlin,China,130041[10]The second hospital of Dalian Medical University Dalian,Liaoning,China,116023
研究目的：
This is a multicenter,open-label,single-arm,phase II study to evaluate the safety and efficacy of Mitoxantrone Hydrochloride Liposome in patients with advanced HER2 negative breast cancer.
